Latest News

Bank of China (SEHK:3988) has just completed a sizeable RMB 60 billion issue of write down tier 2 bonds. The move is aimed squarely at shoring up capital and giving the balance sheet more strategic flexibility. See our latest analysis for Bank of China. Even with the share price easing 4.65% over the last week, Bank of China still carries a solid year to date share price return of around 16%. Its 1 year total shareholder return north of 30% suggests momentum is still broadly constructive as...

If you're not sure where to start when looking for the next multi-bagger, there are a few key trends you should keep an...

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...

As most Gulf markets experience gains driven by rising oil prices and anticipation of a U.S. Federal Reserve rate cut, the Middle East's economic landscape is buzzing with activity and optimism. In this environment, dividend stocks can be particularly appealing as they offer potential income stability amidst fluctuating market conditions, making them an attractive consideration for investors looking to balance growth with steady returns.

One of the best investments we can make is in our own knowledge and skill set. With that in mind, this article will...

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...

While Colgate-Palmolive (India) Limited ( NSE:COLPAL ) shareholders are probably generally happy, the stock hasn't had...

TransThera Sciences (Nanjing) SEHK:2617 has quietly delivered a sharp move over the past 3 months, climbing more than 200%, which naturally raises the question of what the market is now pricing in. See our latest analysis for TransThera Sciences (Nanjing). That surge sits on top of an already extraordinary year to date, with a 726.38% year to date share price return. This suggests investors are rapidly repricing TransThera’s risk and growth prospects, even as near term swings remain...

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...

Australian shares are poised for a modest gain, though recent patterns suggest caution as investors react to market fluctuations. Despite the volatility, penny stocks—often smaller or newer companies—remain an intriguing investment area due to their affordability and potential for growth. When these stocks are supported by strong financial health, they can offer opportunities that defy traditional expectations.

If we want to find a stock that could multiply over the long term, what are the underlying trends we should look for...

NMDC Energy - P.J.S.C.'s ( ADX:NMDCENR ) price-to-earnings (or "P/E") ratio of 8.3x might make it look like a buy right...

By buying an index fund, investors can approximate the average market return. But if you pick the right individual...

UiPath (PATH) just posted Q3 2026 results with revenue of about $411 million and basic EPS of $0.37, putting headline profitability firmly in the black for the quarter. The company has seen revenue move from roughly $355 million in Q3 2025 to $411 million in Q3 2026, while basic EPS swung from a loss of $0.02 to a solid positive print of $0.37, signaling a notable turnaround in quarterly profitability. With that kind of earnings lift on a growing top line, margins are starting to look more...

Hovnanian Enterprises (HOV) just posted its FY 2025 third quarter numbers, with revenue of about $800.6 million and EPS of $2.14, while trailing twelve month revenue came in at roughly $3.1 billion with EPS of $22.16. The company has seen revenue move from $2.8 billion and EPS of $31.63 over the trailing twelve months at Q2 2024 to $3.1 billion and EPS of $22.16 by Q3 2025. This sets up a mixed backdrop of growth at the top line but softer profitability, putting the spotlight firmly on...

Key Insights Significant control over J. B. Chemicals & Pharmaceuticals by private equity firms implies that the...

Pomdoctor (POM) opened H1 2025 with revenue of CNY 192.4 million and basic EPS of CNY -1.49, while the latest trailing twelve month figures show revenue of CNY 342.6 million and EPS of CNY -3.79. The company has seen revenue move from CNY 177.0 million in H2 2023 to CNY 192.4 million in H2 2024, with net income excluding extra items shifting from CNY -71.3 million to CNY -76.6 million over the same period, setting up a story where investors are weighing top line momentum against still...

BETA Technologies (BETA) just posted another loss-making quarter, with Q2 2025 revenue of about $7.8 million and basic EPS of roughly -$12.78, setting the tone for investors heading into the Q3 2025 update at a share price of $29.84. The company has seen revenue climb from around $3.8 million in early 2024 to $7.8 million in early 2025, while EPS deteriorated from about -$9.69 to -$12.78 and trailing twelve month net income slid from roughly -$201.9 million to -$352.5 million. This...

With its stock down 9.3% over the past month, it is easy to disregard Gland Pharma (NSE:GLAND). It is possible that the...

If we want to find a stock that could multiply over the long term, what are the underlying trends we should look for...

Five Below (FIVE) just posted its Q3 2026 report with revenue of about $1.0 billion and EPS of $0.66, alongside net income of roughly $36.5 million as the discount retailer heads into the crucial holiday stretch. The company has seen quarterly revenue move from about $843.7 million in Q3 2025 to $1.0 billion in Q3 2026, while quarterly EPS shifted from near flat at $0.03 in Q3 2025 to $0.66 this quarter. This sets up a story where investors will be weighing solid topline scale against how...

For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...

Key Insights Significant control over Hindware Home Innovation by private companies implies that the general public has...

The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...